Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2012

01-12-2012 | New Horizons In

Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome

Authors: Selma F. Witchel, Sergio E. Recabarren, Frank González, Evanthia Diamanti-Kandarakis, Kai I. Cheang, Antoni J. Duleba, Richard S. Legro, Roy Homburg, Renato Pasquali, Rogerio A. Lobo, Christos C. Zouboulis, Fahrettin Kelestimur, Franca Fruzzetti, Walter Futterweit, Robert J. Norman, David H. Abbott

Published in: Endocrine | Issue 3/2012

Login to get access

Abstract

The interactive nature of the 8th Annual Meeting of the Androgen Excess and PCOS Society Annual Meeting in Munich, Germany (AEPCOS 2010) and subsequent exchanges between speakers led to emerging concepts in PCOS regarding its genesis, metabolic dysfunction, and clinical treatment of inflammation, metabolic dysfunction, anovulation and hirsutism. Transition of care in congenital adrenal hyperplasia from pediatric to adult providers emerged as a potential model for care transition involving PCOS adolescents.
Literature
1.
B.C. Fauser, B.C. Tarlatzis, R.W. Rebar, R.S. Legro, A.H. Balen, R. Lobo, E. Carmina, J. Chang, B.O. Yildiz, J.S. Laven, J. Boivin, F. Petraglia, C.N. Wijeyeratne, R.J. Norman, A. Dunaif, S. Franks, R.A. Wild, D. Dumesic, K. Barnhart, Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 97, 28–38.e25 (2012)
2.
D.H. Abbott, A.F. Tarantal, D.A. Dumesic, Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am. J. Primatol. 71, 776–784 (2009)PubMedCrossRef
3.
4.
B.O. Yildiz, E.S. Knochenhauer, R. Azziz, Impact of obesity on the risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 162–168 (2008)PubMedCrossRef
5.
R. Azziz, C. Marin, L. Hoq, E. Badamgarav, P. Song, Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J. Clin. Endocrinol. Metab. 90, 4650–4658 (2005)PubMedCrossRef
6.
E.O. Talbott, J.V. Zborowski, J.R. Rager, K.E. Kip, X. Xu, T.J. Orchard, Polycystic ovarian syndrome (PCOS): a significant contributor to the overall burden of type 2 diabetes in women. J. Womens Health (Larchmt) 16, 191–197 (2007)CrossRef
7.
F. Alvarez-Blasco, J.I. Botella-Carretero, J.L. San Millan, H.F. Escobar-Morreale, Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch. Intern. Med. 166, 2081–2086 (2006)PubMedCrossRef
8.
R.A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H.F. Escobar-Morreale, W. Futterweit, R. Lobo, R.J. Norman, E. Talbott, D.A. Dumesic, Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95, 2038–2049 (2010)PubMedCrossRef
9.
B. Dilbaz, E. Ozkaya, M. Cinar, E. Cakir, S. Dilbaz, Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 39, 272–277 (2011)PubMedCrossRef
10.
Z.J. Chen, H. Zhao, L. He, Y. Shi, Y. Qin, Y. Shi, Z. Li, L. You, J. Zhao, J. Liu, X. Liang, X. Zhao, J. Zhao, Y. Sun, B. Zhang, H. Jiang, D. Zhao, Y. Bian, X. Gao, L. Geng, Y. Li, D. Zhu, X. Sun, J.E. Xu, C. Hao, C.E. Ren, Y. Zhang, S. Chen, W. Zhang, A. Yang, J. Yan, Y. Li, J. Ma, Y. Zhao, Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat. Genet. 43, 55–59 (2011)PubMedCrossRef
11.
M.O. Goodarzi, M.R. Jones, X. Li, A.K. Chua, O.A. Garcia, Y.D. Chen, R.M. Krauss, J.I. Rotter, W. Ankener, R.S. Legro, R. Azziz, J.F. Strauss 3rd, A. Dunaif, M. Urbanek, Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J. Med. Genet. 49, 90–95 (2012)PubMedCrossRef
12.
H. Zhao, X. Xu, X. Xing, J. Wang, L. He, Y. Shi, Y. Shi, Y. Zhao, Z.J. Chen, Family-based analysis of susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Hum. Reprod. 27, 294–298 (2012)PubMedCrossRef
13.
W. Hu, J. Qiao, Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome. Endocrine 40, 196–202 (2011)PubMedCrossRef
14.
H. Jia, L. Yu, X. Guo, W. Gao, Z. Jiang, Associations of adiponectin gene polymorphisms with polycystic ovary syndrome: a meta-analysis. Endocrine (2012). doi:10.​1007/​s12020-012-9605-3
15.
R. Saxena, C.K. Welt, Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes. Acta Diabetol. (2012) [Epub ahead of print]
16.
R.S. Legro, D. Driscoll, J.F. Strauss 3rd, J. Fox, A. Dunaif, Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc. Natl. Acad. Sci. U.S.A. 95, 14956–14960 (1998)PubMedCrossRef
17.
J.M. Vink, S. Sadrzadeh, C.B. Lambalk, D.I. Boomsma, Heritability of polycystic ovary syndrome in a Dutch twin-family study. J. Clin. Endocrinol. Metab. 91, 2100–2104 (2006)PubMedCrossRef
18.
A.D. Coviello, R.S. Legro, A. Dunaif, Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J. Clin. Endocrinol. Metab. 91, 492–497 (2006)PubMedCrossRef
19.
J.C. Marshall, Obesity in adolescent girls: is excess androgen the real bad actor? J. Clin. Endocrinol. Metab. 91, 393–395 (2006)PubMedCrossRef
20.
W.H. Dietz, Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics 101, 518–525 (1998)PubMed
21.
A.A. Hedley, C.L. Ogden, C.L. Johnson, M.D. Carroll, L.R. Curtin, K.M. Flegal, Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. J. Am. Med. Assoc. 291, 2847–2850 (2004)CrossRef
22.
C.R. McCartney, K.A. Prendergast, S. Chhabra, C.A. Eagleson, R. Yoo, R.J. Chang, C.M. Foster, J.C. Marshall, The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J. Clin. Endocrinol. Metab. 91, 1714–1722 (2006)PubMedCrossRef
23.
C.R. McCartney, Maturation of sleep-wake gonadotrophin-releasing hormone secretion across puberty in girls: potential mechanisms and relevance to the pathogenesis of polycystic ovary syndrome. J. Neuroendocrinol. 22, 701–709 (2010)PubMed
24.
S.K. Blank, C.R. McCartney, K.D. Helm, J.C. Marshall, Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin. Reprod. Med. 25, 352–359 (2007)PubMedCrossRef
25.
S.K. Blank, C.R. McCartney, J.C. Marshall, The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum. Reprod. Update 12, 351–361 (2006)PubMedCrossRef
26.
C.R. McCartney, S.K. Blank, K.A. Prendergast, S. Chhabra, C.A. Eagleson, K.D. Helm, R. Yoo, R.J. Chang, C.M. Foster, S. Caprio, J.C. Marshall, Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J. Clin. Endocrinol. Metab. 92, 430–436 (2007)PubMedCrossRef
27.
R.L. Rosenfield, Clinical review: identifying children at risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 787–796 (2007)PubMedCrossRef
28.
D.H. Geller, D. Pacaud, C.M. Gordon, M. Misra, of the Drug and Therapeutics Committee of the Pediatric Endocrine Society, State of the art review: emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int. J. Pediatr. Endocrinol. 2011, 9 (2011)PubMedCrossRef
29.
S.F. Witchel, R. Azziz, Congenital adrenal hyperplasia. J. Pediatr. Adolesc. Gynecol. 24, 116–126 (2011)PubMedCrossRef
30.
R.J. Auchus, S.F. Witchel, K.R. Leight, J. Aisenberg, R. Azziz et al., Guidelines for the development of comprehensive care centers for congenital adrenal hyperplasia: guidance from the CARES foundation initiative. Int. J. Pediatr. Endocrinol. (2011) [Epub 2011 Jan 10]
31.
W.C. Chen, C.C. Zouboulis, Hormones and the pilosebaceous unit. Dermatoendocrinology 1, 81–86 (2009)CrossRef
32.
H.J. Teede, M.L. Misso, A.A. Deeks, L.J. Moran, B.G. Stuckey, J.L. Wong, R.J. Norman, Guideline Development Groups, Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med. J. Aust. 195, S65–S112 (2011)PubMedCrossRef
33.
D.A. Dumesic, D.H. Abbott, V. Padmanabhan, Polycystic ovary syndrome and its developmental origins. Rev. Endocr. Metab. Disord. 8, 127–141 (2007)PubMedCrossRef
34.
V. Padmanabhan, A. Veiga-Lopez, D.H. Abbott, S.E. Recabarren, C. Herkimer, Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology 151, 595–605 (2010)PubMedCrossRef
35.
A.V. Roland, C.S. Nunemaker, S.R. Keller, S.M. Moenter, Prenatal androgen exposure programs metabolic dysfunction in female mice. J. Endocrinol. 207, 213–223 (2010)PubMedCrossRef
36.
A. Veiga-Lopez, T.L. Steckler, D.H. Abbott, K.B. Welch, P.S. MohanKumar, D.J. Phillips, K. Refsal, V. Padmanabhan, Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep. Biol. Reprod. 84, 87–89 (2011)PubMedCrossRef
37.
C.M. Bruns, S.T. Baum, R.J. Colman, J.R. Eisner, J.W. Kemnitz, R. Weindruch, D.H. Abbott, Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeys. J. Clin. Endocrinol. Metab. 89, 6218–6223 (2004)PubMedCrossRef
38.
S.E. Recabarren, P.P. Rojas-García, M.P. Recabarren, V.H. Alfaro, R. Smith, V. Padmanabhan, T. Sir-Petermann, Prenatal testosterone excess reduces sperm count and motility. Endocrinology 149, 6444–6448 (2008)PubMedCrossRef
39.
P.P. Rojas-García, M.P. Recabarren, L. Sarabia, J. Schön, C. Gabler, R. Einspanier, M. Maliqueo, T. Sir-Petermann, R. Rey, S.E. Recabarren, Prenatal testosterone excess alters Sertoli and germ cell number and testicular FSH receptor expression in rams. Am. J. Physiol. Endocrinol. Metab. 299, E998–E1005 (2010)PubMedCrossRef
40.
A.D. Coviello, S. Sam, R.S. Legro, A. Dunaif, High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity. J. Clin. Endocrinol. Metab. 94, 4361–4366 (2009)PubMedCrossRef
41.
S. Sam, A.D. Coviello, Y.A. Sung, R.S. Legro, A. Dunaif, Metabolic phenotype in the brothers of women with polycystic ovary syndrome. Diabetes Care 31, 1237–1241 (2008)PubMedCrossRef
42.
S. Sam, Y.A. Sung, R.S. Legro, A. Dunaif, Evidence for pancreatic beta-cell dysfunction in brothers of women with polycystic ovary syndrome. Metabolism 57, 84–89 (2008)PubMedCrossRef
43.
R.S. Legro, A.R. Kunselman, L. Demers, S.C. Wang, R. Bentley-Lewis, A. Dunaif, Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87, 2134–2138 (2002)PubMedCrossRef
44.
S.E. Recabarren, R. Smith, R. Rios, M. Maliqueo, B. Echiburú, E. Codner, F. Cassorla, P. Rojas, T. Sir-Petermann, Metabolic profile in sons of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 1820–1826 (2008)PubMedCrossRef
45.
D.H. Abbott, C.R. Bruns, D.K. Barnett, A. Dunaif, T.L. Goodfriend, D.A. Dumesic, A.F. Tarantal, Experimentally induced gestational androgen excess disrupts glucoregulation in rhesus monkey dams and their female offspring. Am. J. Physiol. Endocrinol. Metab. 299, E741–E751 (2010)PubMedCrossRef
46.
S.C. Kent, C.L. Gnatuk, A.R. Kunselman, L.M. Demers, P.A. Lee, R.S. Legro, Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J. Clin. Endocrinol. Metab. 93, 1662–1669 (2008)PubMedCrossRef
47.
T. Sir-Petermann, E. Codner, V. Pérez, B. Echiburú, M. Maliqueo, A. Ladrón de Guevara, J. Preisler, N. Crisosto, F. Sánchez, F. Cassorla, S. Bhasin, Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 94, 1923–1930 (2009)PubMedCrossRef
48.
J.A. Barry, A.R. Kay, R. Navaratnarajah, S. Iqbal, J.E. Bamfo, A.L. David, M. Hines, P.J. Hardiman, Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J. Obstet. Gynaecol. 30, 444–446 (2010)PubMedCrossRef
49.
H. Anderson, N. Fogel, S.K. Grebe, R.J. Singh, R.L. Taylor, A. Dunaif, Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. J. Clin. Endocrinol. Metab. 95, 2180–2186 (2010)PubMedCrossRef
50.
N. Xu, S. Kwon, D.H. Abbott, D.H. Geller, D.A. Dumesic, R. Azziz, X. Guo, M.O. Goodarzi, Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. PLoS One 6(11), e27286 (2011)PubMedCrossRef
51.
D.R. Stewart, B.A. Dombroski, M. Urbanek, W. Ankener, K.G. Ewens, J.R. Wood, R.S. Legro, J.F. Strauss 3rd, A. Dunaif, R.S. Spielman, Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity. J. Clin. Endocrinol. Metab. 91, 4112–4117 (2006)PubMedCrossRef
52.
K.G. Ewens, D.R. Stewart, W. Ankener, M. Urbanek, J.M. McAllister, C. Chen, K.M. Baig, S.C. Parker, E.H. Margulies, R.S. Legro, A. Dunaif, J.F. Strauss 3rd, R.S. Spielman, Family-based analysis of candidate genes for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95, 2306–2315 (2010)PubMedCrossRef
53.
N. Hatzirodos, R.A. Bayne, H.F. Irving-Rodgers, K. Hummitzsch, L. Sabatier, S. Lee, W. Bonner, M.A. Gibson, W.E. Rainey, B.R. Carr, H.D. Mason, D.P. Reinhardt, R.A. Anderson, R.J. Rodgers, Linkage of regulators of TGF-β activity in the fetal ovary to polycystic ovary syndrome. FASEB J. 25, 2256–2265 (2011)PubMedCrossRef
54.
T. Massam-Wu, M. Chiu, R. Choudhury, S.S. Chaudhry, A.K. Baldwin, A. McGovern, C. Baldock, C.A. Shuttleworth, C.M. Klelty, Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF beta. J. Cell Sci. 123(Pt 17), 3006–3018 (2010)PubMedCrossRef
55.
G. Sengle, R.N. Ono, T. Sasaki, L.Y. Sakai, Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J. Biol. Chem. 286, 5087–5099 (2011)PubMedCrossRef
56.
B. Kruse, F.G. Riepe, N. Krone, H.A.G. Bosinski, S. Kloehn, C.J. Partsch, W.G. Sippell, H. Mönig, Congenital adrenal hyperplasia—how to improve the transition from adolescence to adult life. Exp. Clin. Endocrinol. Diabetes 112, 343–355 (2004)PubMedCrossRef
57.
G.S. Conway, Congenital adrenal hyperplasia: adolescence and transition. Horm. Res. 68(suppl 5), 155–157 (2007)PubMedCrossRef
58.
S.D. Grosse, M.S. Schechter, R. Kulkarni, M.A. Lloyd-Puryear, B. Strickland, E. Trevathan, Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics 123, 407–412 (2009)PubMedCrossRef
59.
D. Rosen, Between two worlds: bridging the cultures of child health and adult medicine. J. Adolesc. Health 17, 10–16 (1995)PubMedCrossRef
60.
G.M. Kieckhefer, C.M. Trahms, Supporting development of children with chronic conditions: from compliance toward shared management. Pediatr. Nurs. 26, 354–363 (2000)PubMed
61.
E. Carmina, S.E. Oberfield, R.A. Lobo, The diagnosis of polycystic ovary syndrome in adolescents. Am. J. Obstet. Gynecol. 203, 201.e1–5 (2010)
62.
A. Lindholm, C. Blomquist, M. Bixo, I. Dahlbom, T. Hansson, I. Sundström Poromaa, J. Burén, No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls. Hum. Reprod. 26, 1478–1485 (2011)PubMedCrossRef
63.
D. Glintborg, M. Andersen, B. Richelsen, J.M. Bruun, Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin. Endocrinol. (Oxf) 715, 652–658 (2009)CrossRef
64.
H.F. Escobar-Morreale, M. Luque-Ramírez, F. González, Circulating inflammatory markers in polycystic ovary symdrome: a systematic review and metaanalysis. Fertil. Steril. 95, 1048–1058.e1–2 (2011)
65.
K.A. Toulis, D.G. Goulis, G. Mintziori, E. Kintiraki, E. Eukarpidis, S.A. Mouratoglou, A. Pavlaki, S. Stergianos, M. Poulasouchidou, T.G. Tzellos, A. Makedos, M. Chourdakis, B.C. Tarlatzis, Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum. Reprod. Update 17, 741–760 (2011)PubMedCrossRef
66.
F. González, Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 77, 300–305 (2012)PubMedCrossRef
67.
F. Gonzalez, K.S. Nair, J.K. Daniels, E. Basal, J.M. Schimke, Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women. Am. J. Physiol. Endocrinol. Metab. 302, E297–E306 (2012)PubMedCrossRef
68.
R. Ramasamy, S.J. Vannucci, S.S. Yan, K. Herold, S.F. Yan, A.M. Schmidt, Advanced glycation end products and RAGE: a common threat in aging, diabetes, neurodegeneretion, and inflammation. Glycobiology 15, 16R–28R (2005)PubMedCrossRef
69.
E. Diamanti-Kandarakis, I. Katsikis, C. Piperi, E. Kandaraki, A. Piouka, A.G. Papavassillou, D. Panidis, Increased serum advanced glycation end products is a distinct finding in lean women with PCOS. Clin. Endocrinol. (Oxf) 69, 634–641 (2008)CrossRef
70.
E. Diamanti-Kandarakis, A. Piouka, S. Livadas, C. Piperi, I. Katsikis, A.G. Papavassillou, D. Panidis, Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur. J. Endocrinol. 160, 847–853 (2009)PubMedCrossRef
71.
E. Diamanti-Kandarakis, C. Piperi, E. Patsouris, P. Korkolopoulou, D. Panidis, L. Pawelczyk, A.G. Papavassiliou, A.J. Duleba, Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem. Cell Biol. 127, 581–589 (2007)PubMedCrossRef
72.
K.K. Papachroni, C. Piperi, G. Levidou, P. Korkolopoulou, L. Pawelczyk, E. Diamanti-Kandarakis, A.G. Papavassiliou, Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. J. Cell Mol. Med. 14, 2460–2469 (2010)PubMedCrossRef
73.
I.J. Rzepczynska, P.C. Piotrowski, D.H. Wong, A.B. Cress, J. Villanueva, A.J. Duleba, Role of isoprenylation in simvastatin-induced inhibition of ovarian theca-interstitial growth in the rat. Biol. Reprod. 81, 850–855 (2009)PubMedCrossRef
74.
D. Izquierdo, N. Foyouzi, J. Kwintkiewicz, A.J. Duleba, Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil. Steril. 82(Suppl 3), 1193–1197 (2004)PubMedCrossRef
75.
A. Sokalska, P.C. Piotrowski, I.J. Rzepczynska, A. Cress, A.J. Duleba, Statins inhibit growth of human theca-interstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability. J. Clin. Endocrinol. Metab. 95, 5390–5394 (2010)PubMedCrossRef
76.
B. Banaszewska, L. Pawelczyk, R.Z. Spaczynski, A.J. Duleba, Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J. Clin. Endocrinol. Metab. 96, 3493–3501 (2011)PubMedCrossRef
77.
A.J. Duleba, B. Banaszewska, R.Z. Spaczynski, L. Pawelczyk, Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil. Steril. 85, 996–1001 (2006)PubMedCrossRef
78.
C. Kaya, S.D. Cengiz, B. Berker, S. Demirtas, M. Cesur, G. Erdogan, Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil. Steril. 92, 635–642 (2009)PubMedCrossRef
79.
T. Sathyapalan, E.S. Kilpatrick, A.M. Coady, S.L. Atkin, The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J. Clin. Endocrinol. Metab. 94, 103–108 (2009)PubMedCrossRef
80.
W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, D.M. Nathan, Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002)PubMedCrossRef
81.
L.J. Moran, R. Pasquali, H.J. Teede, K.M. Hoeger, R.J. Norman, Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil. Steril. 92, 1966–1982 (2009)PubMedCrossRef
82.
L.J. Moran, M. Noakes, P.M. Clifton, R.J. Norman, The use of anti-mullerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 3796–3802 (2007)PubMedCrossRef
83.
K.I. Cheang, J.M. Huszar, A.M. Best, S. Sharma, P.A. Essah, J.E. Nestler, Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Diab. Vasc. Dis. Res. 6, 110–119 (2009)PubMedCrossRef
84.
K.A. Jablonski, J.B. McAteer, P.I. de Bakker, P.W. Franks, T.I. Pollin, R.L. Hanson, R. Saxena, S. Fowler, A.R. Shuldiner, W.C. Knowler, D. Altshuler, J.C. Florez, Diabetes Prevention Program Research Group, Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59, 2672–2681 (2010)PubMedCrossRef
85.
A. Gambineri, F. Tomassoni, D.I. Gasparini, A. Di Rocco, V. Mantovani, U. Pagotto, P. Altieri, S. Sanna, A.M. Fulghesu, R. Pasquali, Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95, E204–E208 (2010)PubMedCrossRef
86.
T. Sathyapalan, L.W. Cho, E.S. Kilpatrick, A.M. Coady, S.L. Atkin, A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clin. Endocrinol. (Oxf) 69, 931–935 (2008)CrossRef
87.
G.M. Eid, D.R. Cottam, L.M. Velcu, S.G. Mattar, M.T. Korytkowski, G. Gosman, P. Hindi, P.R. Schauer, Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg. Obes. Relat. Dis. 1, 77–80 (2005)PubMedCrossRef
88.
Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Consensus on infertility treatment related to polycystic ovary syndrome. Fertil. Steril. 89, 505–522 (2008)CrossRef
89.
H. Abu Hashim, M. El-Shafei, A. Badawy, A. Wafa, H. Zaglol, Does laparoscopic ovarian diathermy change clomiphene-resistant PCOS into clomiphene-sensitive? Arch. Gynecol. Obstet. 284, 503–507 (2011)PubMedCrossRef
90.
N.P. Johnson, A.W. Stewart, J. Falkiner, C.M. Farquhar, S. Milsom, V.P. Singh, Q.L. Okonkwo, K.L. Buckingham, REACT-NZ (REproduction And Collaborative Trials in New Zealand), a multi-centre fertility trials group, PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Hum. Reprod. 25, 1675–1683 (2010)PubMedCrossRef
91.
N.P. Polyzos, S. Tzioras, A.M. Badawy, A. Valachis, C. Dritsas, D. Mauri, Aromatase inhibitors for female infertility: a systematic review of the literature. Reprod. Biomed. Online 19, 456–471 (2009)PubMedCrossRef
92.
T.D. Vause, A.P. Cheung, S. Sierra, P. Claman, J. Graham, J.A. Guillemin, L. Lapensée, S. Steward, B.C. Wong, Society of Obstetricians and Gynaecologists of Canada, Ovulation induction in polycystic ovary syndrome: No. 242, May 2010. Int. J. Gynaecol. Obstet. 111, 95–100 (2010)PubMedCrossRef
93.
D. Tredway, J.C. Schertz, D. Bock, G. Hemsey, M.P Diamond, Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction: a phase II, randomized, dose-finding study. Fertil. Steril. 95, 1720–4.e1–8 (2011)
94.
T. Tulandi, J. Martin, R. Al-Fadhli, N. Kabli, R. Forman, J. Hitkari, C. Librach, E. Greenblatt, R.F. Casper, Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil. Steril. 85, 1761–1765 (2006)PubMedCrossRef
95.
S. Palomba, A. Falbo, F. Zullo, F. Orio Jr, Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30, 1–50 (2009)PubMedCrossRef
96.
R. Pasquali, A. Gambineri, U. Pagotto, The impact of obesity on reproduction in women with polycystic ovary syndrome. Br. J. Obstet. Gynecol. 113, 1148–1159 (2006)CrossRef
97.
E. Diamanti-Kandarakis, C.D. Christakou, E. Kandaraki, F.N. Economou, Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur. J. Endocrinol. 162, 193–212 (2010)PubMedCrossRef
98.
R.S. Legro, H.X. Barnhart, W.D. Schlaff, B.R. Carr, M.P. Diamond, S.A. Carson, M.P. Steinkampf, C. Coutifaris, P.G. McGovern, N.A. Cataldo, G.G. Gosman, J.E. Nestler, L.C. Giudice, P.C. Leppert, E.R. Myers, Cooperative Multicenter Reproductive Medicine Network. Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome. N. Engl. J. Med. 356, 551–566 (2007)PubMedCrossRef
99.
S. Palomba, R. Pasquali, F. Orio Jr, J.E. Nestler, Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin. Endocrinol. (Oxf) 70, 311–321 (2009)CrossRef
100.
A.A. Creanga, H.M. Bradley, C. McCormick, C.T. Witkop, Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet. Gynecol. 111, 959–968 (2008)PubMedCrossRef
101.
S. Franks, When should an insulin sensitizing agent used in the treatment of polycystic ovary syndrome? Clin. Endocrinol. (Oxf) 74, 148–151 (2011)CrossRef
102.
E. Makrantonaki, C.C. Zouboulis, Androgens and ageing of the skin. Curr. Opin. Endocrinol. Diabetes Obes. 16, 240–245 (2009)PubMedCrossRef
103.
C.C. Zouboulis, The human skin as a hormone target and an endocrine gland. Hormones (Athens) 3, 9–26 (2004)
104.
C.C. Zouboulis, The skin as an endocrine organ. Dermatoendocrinology 1, 250–252 (2009)CrossRef
105.
C.C. Zouboulis, W.C. Chen, M.J. Thornton, K. Qin, R. Rosenfield, Sexual hormones in human skin. Horm. Metab. Res. 39, 85–95 (2007)PubMedCrossRef
106.
A. Drosdzol, V. Skrzypulec, R. Plinta, Quality of life, mental health and self-esteem in hirsute adolescent females. J. Psychosom. Obstet. Gynaecol. 31, 168–175 (2010)PubMedCrossRef
107.
H.F. Escobar-Morreale, E. Carmina, D. Dewailly, A. Gambineri, F. Kelestimur, P. Moghetti, M. Pugeat, J. Qiao, C.N. Wijeyaratne, S.F. Witchel, R.J. Norman, Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum. Reprod. Update 18, 146–170 (2012)
108.
109.
R. Paparodis, A. Dunaif, The Hirsute woman: challenges in evaluation and management. Endocr. Pract. 17, 807–818 (2011)PubMedCrossRef
110.
F. Lumachi, S.M. Basso, Medical treatment of hirsutism in women. Curr. Med. Chem. 17, 2530–2538 (2010)PubMedCrossRef
111.
R. Sinclair, M. Patel, T.L. Dawson Jr, A. Yazdabadi, L. Yip, A. Perez, N.W. Rufaut, Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br. J. Dermatol. 165(Suppl 3), 12–18 (2011)PubMedCrossRef
112.
M. Yamaoka, T. Hara, T. Hitaka, T. Kaku, T. Takeuchi, J. Takahashi, S. Asahi, H. Miki, A. Tasaka, M. Kusaka, Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J. Steroid. Biochem. Mol. Biol. 129, 115–128 (2012)PubMedCrossRef
Metadata
Title
Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome
Authors
Selma F. Witchel
Sergio E. Recabarren
Frank González
Evanthia Diamanti-Kandarakis
Kai I. Cheang
Antoni J. Duleba
Richard S. Legro
Roy Homburg
Renato Pasquali
Rogerio A. Lobo
Christos C. Zouboulis
Fahrettin Kelestimur
Franca Fruzzetti
Walter Futterweit
Robert J. Norman
David H. Abbott
Publication date
01-12-2012
Publisher
Springer US
Published in
Endocrine / Issue 3/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9701-4

Other articles of this Issue 3/2012

Endocrine 3/2012 Go to the issue

Original Article

Diagnostic value of antithyroid peroxidase antibody for incidental autoimmune thyroiditis based on histopathologic results

Original Article

Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer

Editorial

Anaplastic thyroid cancer therapy: dream or reality?

Original Article

Parathyroid incidentalomas detected during thyroid ultrasonography and effect of chronic thyroiditis on false positive parathyroid lesions

Original Article

The study of soluble intercellular adhesion molecule-1 and ghrelin in adolescents with family history of type 2 diabetes

Original Article

Nesfatin-1 and other hormone alterations in polycystic ovary syndrome

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits